Anzeige
Mehr »
Donnerstag, 10.09.2026 - Börsentäglich über 12.000 News
Mehr als 4,5 Mrd. USD US-Staatsgeld für alte Bohrlöcher, diese Aktie räumt auf
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2DP4W | ISIN: SE0009607252 | Ticker-Symbol: 2E9
Frankfurt
10.09.26 | 08:07
0,071 Euro
+0,14 % +0,000
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
INTERVACC AB Chart 1 Jahr
5-Tage-Chart
INTERVACC AB 5-Tage-Chart
RealtimeGeldBriefZeit
0,0600,12420:41

Aktuelle News zur INTERVACC Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
20.08.Intervacc AB: Interim report January - June 2026146THE GROUP IN SUMMARY THE GROUP APRIL - JUNE JAN - JUNE FULL YEAR 2026 2025 2026 2025 2025 Net...
► Artikel lesen
30.07.Intervacc AB: Intervacc submits Type II variation to EMA seeking 12-month duration of immunity for Strangvac229Intervacc AB (publ) today announces that it has submitted a Type II variation application to the European Medicines Agency (EMA) for Strangvac, the company's innovative vaccine against strangles in...
► Artikel lesen
INTERVACC Aktie jetzt für 0€ handeln
29.07.Intervacc AB: Intervacc makes first export of Strangvac to New Zealand under Special Circumstances Permit419Intervacc AB (publ) today announces that Strangvac, the company's innovative vaccine against strangles in horses, has been approved for import into New Zealand under a Special Circumstances Permit....
► Artikel lesen
22.05.Intervacc AB: Intervacc completes successful evaluation of US strain of strangles pathogen ahead of clinical trials197Intervacc AB (publ), a Swedish growth company specialising in animal vaccines, has completed the evaluation of a US strain of Streptococcus equi in US horses prior to its use in a clinical trial towards...
► Artikel lesen
15.05.Emil Billbäck appointed new Chair of the Board of Intervacc2
13.05.Intervacc AB: Report from Annual General Meeting in Intervacc199Intervacc AB (publ) held its Annual General Meeting ("AGM") on Wednesday 13 May 2026, at which the following resolutions were made. Adoption of the income statement and balance sheet The AGM adopted...
► Artikel lesen
13.05.Intervacc AB Q1 Sales Decline1
12.05.Intervacc AB: Intervacc strengthens management team for future growth287Intervacc AB (publ), a Swedish growth company in animal health with the vaccine Strangvac registered on 16 European markets, today announces that the company is strengthening its management team through...
► Artikel lesen
12.05.Intervacc AB: Interim report January - March 2026241The Group in summary 01/01/26 01/01/25 01/01/25 -31/03/26 -31/03/25 -31/12/25 Net...
► Artikel lesen
04.05.INTERVACC AB: International Awareness Initiative Against Strangles2
23.04.Intervacc brings together leading US and European experts to jointly tackle strangles2
16.04.Intervacc AB: Unprecedented decision opens the way for the launch of Strangvac in Iceland233Intervacc AB (publ) announces that Strangvac, the company's innovative vaccine against strangles in horses, has been approved by the authorities in Iceland. Strangles, a potentially lethal infection...
► Artikel lesen
14.04.Intervacc publishes the 2025 Annual Report1
10.04.Notice of Annual General Meeting in Intervacc AB (publ)1
19.03.Intervacc AB: Intervacc announces breakthrough protection against Streptococcus suis infection in piglets265Intervacc AB (publ) is first in the world to show that piglets were protected against the virulent and severe disease-causing S. suis Sequence Types 1 and 16 (serotype 2 and 9, respectively), by vaccinating...
► Artikel lesen
17.02.Intervacc AB: Year-end report January - December 2025318The Group in summary 01/10/25 01/10/24 Full year Full year -31/12/25 -31/12/24 2025 2024 Net...
► Artikel lesen
05.02.Intervacc AB: Intervacc announces change of CEO381The Board of Directors of Intervacc AB (publ), together with Jonas Sohlman, has agreed that he will leave his role as Chief Executive Officer and Group CEO. Simultaneously, the Board has appointed...
► Artikel lesen
16.12.25Intervacc AB: Clinical studies with Strangvac have begun in the U.S. market258Intervacc AB (publ) announces that the company has started the first phase of clinical safety studies in horses in the United States as part of the approval process for Strangvac in the U.S. The initial...
► Artikel lesen
19.11.25Intervacc AB: Interim report January - September 2025251The Group in summary 01/07/25 01/07/24 01/01/25 01/01/24 Full year -30/09/25 -30/09/24 -30/09/25 -30/09/24 2024 Net...
► Artikel lesen
13.10.25Intervacc AB: Intervacc and Dechra extend distribution agreement for Intervacc's equine strangles vaccine Strangvac by two years276Intervacc AB (publ) announces today that the five-year distribution agreement signed in April 2021 with its partner Dechra Pharmaceuticals PLC has been extended by two years. The extension will take...
► Artikel lesen
20 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1